Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Medivation Inc    MDVN   US58501N1019


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Medivation Inc : Medivation Announces Participation at Upcoming Investor Conferences

10/30/2013 | 04:34pm US/Eastern

SAN FRANCISCO, CA -- (Marketwired) -- 10/28/13 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss third quarter 2013 financial results and provide a general business update on November 12, 2013 at 4:30 p.m. Eastern Time. A press release for the third quarter of 2013 will be released after markets close on November 12, 2013.

Interested parties may listen to the live teleconference by calling 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals may access the live audio webcast by visiting:

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at

Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900

Source: Medivation

News Provided by Acquire Media

distributed by
React to this article
Latest news on MEDIVATION INC
01:41a MEDIVATION : and Astellas Pharma Reports Results from Phase 2 Terrain Trial
01/28 MEDIVATION : and Astellas Pharma Releases Results from Phase 2 Terrain Trial
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 MEDIVATION : Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Signi..
2014 MEDIVATION : exercises license option for Pidilizumab
2014 ISRAEL : Housing and Construction Ltd. in giant Berlin property deal
2014 MEDIVATION : Exercises License Option for Pidilizumab
2014 MEDIVATION : takes up $335m Curetech licensing option
2014 MEDIVATION : Announces Participation at Upcoming Investor Conference
2014 MEDIVATION : Data presented from phase 2 study of enzalutamide in advanced andro..
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes